Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Introduction: Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of insulin-like growth factor I (IGF-I). Transsphenoidal surgery is the treatment of choice, although many patients require additional interv...

Full description

Bibliographic Details
Main Authors: Mônica Gadelha, Marie Bex, Annamaria Colao, Elier Mitsael Pedroza García, Catalina Poiana, Marisela Jimenez-Sanchez, Serkan Yener, Rishav Mukherjee, Amy Bartalotta, Ricardo Maamari, Gérald Raverot
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Endocrinology
Subjects:
somatostatin
pasireotide
acromegaly
growth hormone
insulin-like growth factor I
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2019.00931/full

Similar Items

Similar Items